Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AGIO Agios Pharmaceuticals

Not Yet Opened 03-10 16:00:00 EDT

28.26

-0.27

-0.95%

盘后28.26

+0.000.00%

16:10 EDT

High28.97	Low28.00	Vol526.67K
Open28.51	D1 Closing28.53	Amplitude3.40%
Mkt Cap1.65B	Tradable Cap1.45B	Total Shares58.31M
T/O14.92M	T/O Rate1.03%	Tradable Shares51.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AGIO","market":"US","secType":"STK","nameCN":"Agios Pharmaceuticals","latestPrice":28.26,"timestamp":1773172800000,"preClose":28.53,"halted":0,"volume":526668,"hourTrading":{"tag":"盘后","latestPrice":28.26,"preClose":28.26,"latestTime":"16:10 EDT","volume":7854,"amount":221954.04,"timestamp":1773173404954,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.009463722397476325,"floatShares":51348506,"shares":58313812,"eps":-7.12035,"marketStatus":"Not Yet Opened","change":-0.27,"latestTime":"03-10 16:00:00 EDT","open":28.51,"high":28.97,"low":28,"amount":14920177.622386,"amplitude":0.033999,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.12035,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773216000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1374638400000,"exchange":"NASDAQ","adjPreClose":28.53,"preHourTrading":{"tag":"盘前","latestPrice":28.38,"preClose":28.53,"latestTime":"09:02 EDT","volume":9,"amount":256.519998,"timestamp":1773147761714,"change":-0.15,"changeRate":-0.005258,"amplitude":0.012268},"postHourTrading":{"tag":"盘后","latestPrice":28.26,"preClose":28.26,"latestTime":"16:10 EDT","volume":7854,"amount":221954.04,"timestamp":1773173404954,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.585972,"impliedVol":0.3783,"impliedVolPercentile":0.0558},"requestUrl":"/m/hq/s/AGIO/tweets","defaultTab":"tweets","newsList":[{"id":"2617768495","title":"Agios Pharmaceuticals Principal Accounting Officer Theodore James Jr. Washburn Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617768495","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617768495?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:08","pubTimestamp":1772744934,"startTime":"0","endTime":"0","summary":"Theodore James Jr. Washburn, Principal Accounting Officer of Agios Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL8JZgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Agios Pharmaceuticals Principal Accounting Officer Theodore James Jr. Washburn Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2617832573","title":"Agios Pharmaceuticals Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2617832573","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617832573?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:46","pubTimestamp":1772739960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2026 14:46 ET (19:46 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0},{"id":"2616539224","title":"Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2616539224","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616539224?lang=en_us&edition=fundamental","pubTime":"2026-03-04 18:35","pubTimestamp":1772620546,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.\nThis approval, supported by global Phase 3 ENERGIZE and ENERGIZE-T data and backed by a regional partnership with NewBridge Pharmaceuticals, strengthens Agios’s push into Gulf markets for rare blood disorder treatments.\nNext, we’ll examine...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-down-63-after-uae-clears-pyruk","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-down-63-after-uae-clears-pyruk","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UAE","AGIO","BK4139"],"gpt_icon":0},{"id":"2616331681","title":"Agios Pharmaceuticals Inc - Newbridge to Manage Pyrukynd Commercialization in Gulf","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331681?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:06","pubTimestamp":1772453163,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0QF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2616316833","title":"Agios’ Pyrukynd® (Mitapivat) Approved for Adults With Thalassemia in the United Arab Emirates","url":"https://stock-news.laohu8.com/highlight/detail?id=2616316833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616316833?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:06","pubTimestamp":1772453163,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0QF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2616331867","title":"UAE Regulator Approves Agios PYRUKYND for Adult Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331867","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331867?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:01","pubTimestamp":1772452898,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals Inc. said the Emirates Drug Establishment of the United Arab Emirates has approved PYRUKYND  for treating adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The company added that NewBridge Pharmaceuticals will continue to manage commercialization of PYRUKYND in the Gulf region under a distribution agreement covering the GCC countries.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDLbX0BCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","BK4588","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210149790.SGD","AGIO","LU0314104364.USD","SG9999014013.SGD","IE00BGHQF748.EUR","SG9999014039.USD","LU2095319765.USD","BK4139","IE00BKPKM429.USD","NDAQ","BK4585"],"gpt_icon":0},{"id":"2611119186","title":"Agios Pharmaceuticals (AGIO) Valuation Check As Shares Trade Near Recent Levels And PYRUKYND Prospects Evolve","url":"https://stock-news.laohu8.com/highlight/detail?id=2611119186","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611119186?lang=en_us&edition=fundamental","pubTime":"2026-02-14 15:28","pubTimestamp":1771054104,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) has drawn investor attention after recent trading moves, with the stock last closing at $27.96. You might be weighing how its current performance lines up with the company’s underlying fundamentals.\nSee our latest analysis for Agios Pharmaceuticals.\nRecent moves around $27.96 come after a mixed stretch, with a 7 day share price return of 5.39% but a 90 day share price return of 35.95% and a 1 year total shareholder return decline of 15.83%, suggesting earlier...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-valuation-check-as-shares-trade-n","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-valuation-check-as-shares-trade-n","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2611197898","title":"RBC Capital Sticks to Their Hold Rating for Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611197898","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611197898?lang=en_us&edition=fundamental","pubTime":"2026-02-14 09:46","pubTimestamp":1771033569,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Hold rating on Agios Pharma on February 12 and set a price target of $28.00. According to TipRanks, Issi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-agios-pharma-agio-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-agios-pharma-agio-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"gpt_icon":0},{"id":"2611157961","title":"Truist Financial Keeps Their Buy Rating on Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611157961","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611157961?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:16","pubTimestamp":1770988614,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Gregory Renza maintained a Buy rating on Agios Pharma today and set a price target of $39.00. Renza covers the Healthcare ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-agios-pharma-agio-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-agios-pharma-agio-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"gpt_icon":0},{"id":"2611155206","title":"Agios Pharmaceuticals Inc : Leerink Partners Raises Target Price to $47.00 From $39.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2611155206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611155206?lang=en_us&edition=fundamental","pubTime":"2026-02-13 19:13","pubTimestamp":1770981237,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z913U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2611138644","title":"U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections","url":"https://stock-news.laohu8.com/highlight/detail?id=2611138644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611138644?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:43","pubTimestamp":1770965029,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections Feb 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nL4N3Z90HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FIAT","TXG","COIN","BAX","COYY","COIO","ADI","BIO","CBRE","EEFT","ETR","CONX","COR","AMAT","CLYM","DXCM","COIA","DLTR","ALNY","COIG","ABNB","AEP","COHR","EXC","DBD","BROS","LU1861215975.USD","APP","ANET","AVNT","AMG","ECL","APPX","ALB","CGNX","AGIO","CW","AEE","CONL","BRKR","CONI","CONY","COIW","DKNG","CRSR","BDC","DAR","BFAM","CROX","BBIO"],"gpt_icon":1},{"id":"2611879881","title":"Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2611879881","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611879881?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:01","pubTimestamp":1770962483,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) has disclosed a new risk, in the Regulation category. Agios Pharmaceuticals faces heightened regulatory timing risk as...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-delays-threaten-agios-pharmaceuticals-drug-pipeline-costs-and-revenue-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-delays-threaten-agios-pharmaceuticals-drug-pipeline-costs-and-revenue-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"gpt_icon":0},{"id":"2611042089","title":"Agios Pharmaceuticals Signals Confident Path After Afesmi Win","url":"https://stock-news.laohu8.com/highlight/detail?id=2611042089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611042089?lang=en_us&edition=fundamental","pubTime":"2026-02-13 08:25","pubTimestamp":1770942314,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (($AGIO)) has held its Q4 earnings call. Read on for the main highlights of the call. Agios Pharmaceuticals’ latest earnings ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/agios-pharmaceuticals-signals-confident-path-after-afesmi-win?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/agios-pharmaceuticals-signals-confident-path-after-afesmi-win?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2611597004","title":"Agios Pharmaceuticals Files for Mixed Shelf Offering; Size Not Disclosed - Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2611597004","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611597004?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:20","pubTimestamp":1770931207,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z81I8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2611296971","title":"Agios Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2611296971","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611296971?lang=en_us&edition=fundamental","pubTime":"2026-02-13 03:10","pubTimestamp":1770923400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2026 14:10 ET (19:10 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0},{"id":"2611976012","title":"Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2611976012","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611976012?lang=en_us&edition=fundamental","pubTime":"2026-02-13 01:25","pubTimestamp":1770917138,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Agios Pharma today and set a price target of $65.00. Emily Bodnar has given his Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/agios-pharmaceuticals-early-aqvesme-traction-and-rems-driven-uptake-support-robust-mitapivat-growth-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/agios-pharmaceuticals-early-aqvesme-traction-and-rems-driven-uptake-support-robust-mitapivat-growth-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"gpt_icon":0},{"id":"2610923690","title":"Agios reports FY 2025 net income loss of USD 412.8 million and PYRUKYND net revenues of USD 54 million, up 48 percent","url":"https://stock-news.laohu8.com/highlight/detail?id=2610923690","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610923690?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:06","pubTimestamp":1770898000,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL8TS3Ry:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"gpt_icon":0},{"id":"2610923341","title":"Agios Pharmaceuticals Q4 Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2610923341","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610923341?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:02","pubTimestamp":1770897768,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) reported Q4 revenue of $20 million, up from $10.7 million a year earlier.Analysts polled by FactSet expected $12.1 million.As of Dec. 31, the company had cash, cash equivalents and marketable securities of $1.2 billion.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGIO"],"gpt_icon":0},{"id":"2610794014","title":"Agios 2025 product revenue beats analyst estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2610794014","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610794014?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:38","pubTimestamp":1770896318,"startTime":"0","endTime":"0","summary":"Agios 2025 product revenue beats analyst estimatesOverviewBiopharmaceutical firm's 2025 product revenue beat analyst expectationsCompany reported net loss of $108 mln for Q4 2025Company holds $1.2 bln","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z80K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"gpt_icon":0},{"id":"2610940197","title":"Agios Pharmaceuticals Q4 EPS $(1.86) Beats $(1.94) Estimate, Sales $19.967M Beat $12.014M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2610940197","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610940197?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:35","pubTimestamp":1770896108,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(1.94) by 3.93 percent. This is a 4.12 percent increase over losses of $(1.94) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50569896/agios-pharmaceuticals-q4-eps-1-86-beats-1-94-estimate-sales-19-967m-beat-12-014m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agios.com","stockEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":0.0652},{"period":"3month","weight":0.0093},{"period":"6month","weight":-0.2258},{"period":"1year","weight":-0.1166},{"period":"ytd","weight":0.0382}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0195},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0297},{"period":"1year","weight":0.208},{"period":"ytd","weight":-0.007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.846154,"avgChangeRate":0.040392},{"month":2,"riseRate":0.692308,"avgChangeRate":0.060535},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.015768},{"month":4,"riseRate":0.583333,"avgChangeRate":0.006741},{"month":5,"riseRate":0.583333,"avgChangeRate":0.052252},{"month":6,"riseRate":0.666667,"avgChangeRate":0.045835},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.012275},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.041451},{"month":9,"riseRate":0.538462,"avgChangeRate":0.042929},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.007074},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033339},{"month":12,"riseRate":0.384615,"avgChangeRate":-0.051358}],"exchange":"NASDAQ","name":"Agios Pharmaceuticals","nameEN":"Agios Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agios Pharmaceuticals,AGIO,Agios Pharmaceuticals股票,Agios Pharmaceuticals股票老虎,Agios Pharmaceuticals股票老虎国际,Agios Pharmaceuticals行情,Agios Pharmaceuticals股票行情,Agios Pharmaceuticals股价,Agios Pharmaceuticals股市,Agios Pharmaceuticals股票价格,Agios Pharmaceuticals股票交易,Agios Pharmaceuticals股票购买,Agios Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}